Recursion Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-11-05
- Employees
- 500
- Market Cap
- $2.1B
- Website
- http://www.recursion.com
- Introduction
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.
Artificial Intelligence (AI) in Biotechnology Market Industry
The AI in Biotechnology Market is projected to grow from USD 2.10 Bn in 2024 to USD 7.11 Bn by 2031, at a CAGR of 19%. Key opportunities include increased diagnostic accuracy, personalized therapies, revolutionized drug discovery, advanced genomic analytics, and integrated healthcare systems. Major players analyzed include AstraZeneca, Bristol-Myers Squibb, and Gilead Sciences Inc.
How Generative AI Will Find a Place in the Pharma Industry Now and in the Years to Come
Generative AI is transforming pharma by automating labor-intensive tasks, aiding drug discovery, optimizing clinical trials, and predicting patient outcomes. Despite high upfront costs, AI's value lies in faster, more efficient, and successful trials, potentially leading to leaner, tech-savvy pharma companies with new business models.
Iktos appoints new scientific advisory board with renowned AI and drug discovery experts
Iktos appoints a new Scientific Advisory Board with experts in AI-driven molecular design, lab automation, computational chemistry, first-in-human drug development, and strategic pipeline management to enhance its AI-first drug discovery platform.
Recursion's Fast-Track Road to Therapeutics Using AI-Based Maps of Biology
Recursion's AI platform developed REC-1245, a drug for solid tumors and lymphoma, progressing from target to preclinical candidate in under 18 months. The drug selectively degrades RBM39, offering a new therapeutic approach for resistant tumors. Industry experts note the potential of AI in speeding up drug discovery timelines, though the impact on phase transition likelihood remains uncertain.
1 AI Biotech Stock That Just Scored a Major Milestone
AI-powered Recursion Pharmaceuticals (RXRX) hit a milestone with FDA approval for REC-1245, targeting RBM39 in advanced cancers. The company plans to merge with Exscientia (EXAI) in 2025 and has partnerships with Bayer (BAYZF) and Sanofi (SNY), with an average 12-month target price of $10.14 for RXRX stock.
Chief Executive Officer Gibson Christopher converted options into 40,000 shares and sold ...
Recursion appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer, also joining the Board of Directors. Khan will lead R&D and build commercial capabilities.
Director Borgeson Blake was granted 2,026 shares, increasing direct ownership by 0.03% to ...
Recursion appoints Najat Khan, PhD, as Chief R&D and Commercial Officer, also joining the Board of Directors. Khan brings expertise in biological, chemical, and medical sciences, data science, and business.
Recursion Obtains FDA Approval For AI-Discovered Cancer Treatment Clinical Trial
Recursion's REC-1245, a new chemical entity for biomarker-enriched solid tumours and lymphoma, received FDA clearance for a Phase 1/2 clinical trial. The trial will assess REC-1245's safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy, with initiation expected in Q4. REC-1245 is a potent and selective RBM39 degrader, targeting tumours resistant to conventional treatments, potentially benefiting over 100,000 patients in the US and EU5.
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Recursion Pharmaceuticals' AI platform identified a drug candidate for solid tumors and lymphoma, gaining FDA approval for a phase 1/2 trial in under 18 months. The potential market exceeds 100,000 patients in the U.S. and EU. The trial will start in Q4 2024, targeting RBM39 in advanced HR-proficient cancers.
© Copyright 2025. All Rights Reserved by MedPath